share_log

HOOKIPA Pharma | 10-K: FY2024 Annual Report

SEC ·  Feb 28 16:40

Summary by Moomoo AI

Hookipa, a clinical-stage biopharmaceutical company, reported FY2024 revenue of $43.9M, up 118% YoY from $20.1M. The company narrowed its net loss to $43.5M from $81.6M in 2023, with operating expenses decreasing to $95.4M from $117.8M. Basic and diluted loss per share improved to $3.47 from $8.63, while cash position stood at $39.9M as of December 31, 2024.The company implemented significant strategic restructuring in 2024, including multiple workforce reductions totaling 130%. Development of Eseba-vec was paused in November 2024, while HB-700 for KRAS-mutated cancers is Phase 1-ready with first dosing expected mid-2025. The Gilead partnership programs progressed with HB-400 in Phase 1 for Hepatitis B and HB-500 entering Phase 1b trials for HIV.Despite operational progress, Hookipa faces substantial going concern uncertainties with an accumulated deficit of $412.8M. The company maintains significant tax loss carryforwards of $400.9M in Austria and $9.5M in the U.S., while terminating Poolbeg Pharma acquisition discussions in February 2025. Management recorded $2.7M in restructuring charges and has $4.7M in CMO obligations for 2025.
Hookipa, a clinical-stage biopharmaceutical company, reported FY2024 revenue of $43.9M, up 118% YoY from $20.1M. The company narrowed its net loss to $43.5M from $81.6M in 2023, with operating expenses decreasing to $95.4M from $117.8M. Basic and diluted loss per share improved to $3.47 from $8.63, while cash position stood at $39.9M as of December 31, 2024.The company implemented significant strategic restructuring in 2024, including multiple workforce reductions totaling 130%. Development of Eseba-vec was paused in November 2024, while HB-700 for KRAS-mutated cancers is Phase 1-ready with first dosing expected mid-2025. The Gilead partnership programs progressed with HB-400 in Phase 1 for Hepatitis B and HB-500 entering Phase 1b trials for HIV.Despite operational progress, Hookipa faces substantial going concern uncertainties with an accumulated deficit of $412.8M. The company maintains significant tax loss carryforwards of $400.9M in Austria and $9.5M in the U.S., while terminating Poolbeg Pharma acquisition discussions in February 2025. Management recorded $2.7M in restructuring charges and has $4.7M in CMO obligations for 2025.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Doc 6

Doc 7

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 236
Related Stocks Related Stocks
Symbol Mini Chart Price
LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
LEXXW
0.2597
Syros Pharmaceuticals
SYRS
0.0924
Anebulo Pharmaceuticals
ANEB
1.710
Akari Therapeutics
AKTX
1.0800
Zura Bio
ZURA
1.280
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stocks keep rallying: What will drive the next move?
🎙️Discussion 1. With the government's emphasis on technological innovation and sustainability, which industry sectors do you believe hold t Show More
Do you think the policies during the two sessions will boost Chinese stocks?
81%
19%
Bullish
Bearish
2271 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....